Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 15/20 | 0.48 |
| ▸ | CASP6 | P55212 | 13/20 | 0.48 |
| ▸ | CASP8 | Q14790 | 13/20 | 0.48 |
| ▸ | CASP1 | P29466 | 4/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14068158 | 0.96 | CASP3 (0.44) | CASP3CASP6CASP8CASP1ITGB1 | |
| SCHEMBL6611925 | 0.93 | CASP3 (0.48) | CASP3CASP6CASP8CASP1ITGB1 | |
| SCHEMBL14067881 | 0.88 | CASP3 (0.48) | CASP3CASP6CASP8CASP1ITGB1 | |
| SCHEMBL6613452 | 0.88 | CASP3 (0.45) | CASP3CASP6CASP8CASP1ITGB1 | |
| SCHEMBL6612006 | 0.86 | CASP3 (0.41) | CASP3CASP6CASP8ITGB1ITGA4 | |
| SCHEMBL6625593 | 0.86 | CASP1 (0.41) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL6610884 | 0.85 | CASP3 (0.39) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL6610133 | 0.85 | CASP3 (0.47) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL6611761 | 0.85 | CASP3 (0.47) | CASP3CASP6CASP8CASP1ITGB1 | |
| SCHEMBL6613189 | 0.85 | CASP3 (0.45) | CASP3CASP6CASP8CASP1ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212056-A1 | COMBINATION THERAPY FOR THE TREATMENT OF LIVER DISEASES | CONATUS PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| WO-2008106167-A1 | COMBINATION THERAPY COMPRISING MATRIX METALLOPROTEINASE INHIBITORS AND CASPASE INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | CONATUS PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207605-A1 | Combination therapy for the treatment of liver diseases | CONATUS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207605-A1 | Combination therapy for the treatment of liver diseases | CONATUS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212056-A1 | COMBINATION THERAPY FOR THE TREATMENT OF LIVER DISEASES | MMP10, MMP3, GOT2 | CASP3 67/4885CASP6 43/4885CASP8 82/4885 |
| US-20080207605-A1 | Combination therapy for the treatment of liver diseases | MMP10, MMP3, GOT2 | CASP3 67/4885CASP6 43/4885CASP8 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.